The Dow Jones industrials still held a loss of 0.3% after the index pared a steeper loss. Blue-chip stocks like Nvidia NVDA, ...

Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the ...

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

The Tremfya Market is expanding due to a rising demand for targeted therapies in chronic autoimmune conditions like plaque ...

Nanoparticles enhance drug solubility, stability, and bioavailability, improving therapeutic outcomes for GI conditions like IBD through targeted delivery mechanisms. Hydrogel-based systems offer ...

ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new ...